ClinicalTrials.govpublic full text
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
breast cancer, early stage, high risk, node positive, doxorubicin, cyclophosphamide, paclitaxel, sorafenib, interventional, na
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 880400
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.